In fact, somatic inactivation of NF1 in hematopoietic cells results in a progressive myeloproliferative disorder in mice, with elevated levels of RAS-GTP [24], although secondary genetic events are required to the development of AML. This evidence concerns the gene NF1 and myeloproliferative disorder.